COMMUNIQUÉS West-GlobeNewswire

Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
20/02/2024
Event to feature KOL perspective on emerging MASH therapies SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company [...]
Tonix Pharmaceuticals to Participate in the 2024 BIO CEO & Investor Conference
20/02/2024
CHATHAM, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, [...]
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
20/02/2024
WILMETTE, Ill., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced it [...]
NMDP Announces Enrollment of First Patient in OPTIMIZE Clinical Trial
20/02/2024
Groundbreaking Trial Seeks to Enhance Blood Cancer Treatment Efficacy and Safety MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- NMDP SM (formerly known as the National Marrow Donor Program), home to the most diverse [...]
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
20/02/2024
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in [...]
Clinical Research Data Sharing Alliance (CRDSA) Hosts Virtual Summit
20/02/2024
The Patient Data Revolution: From Promise to Realization PISCATAWAY, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- The Clinical Research Data Sharing Alliance (CRDSA) is convening leading experts from the scientific and [...]
ProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMART
20/02/2024
Garden City, NY, Feb. 20, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, today announced important developments in the Company’s efforts to [...]
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
20/02/2024
BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported publication of United States [...]
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
20/02/2024
BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of [...]
Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its Lead Oncology Program
20/02/2024
Global thought leaders join advisory team to focus on Mestag’s groundbreaking tertiary lymphoid structure (TLS) induction approach to treat solid tumors CAMBRIDGE, United Kingdom, Feb. 20, 2024 (GLOBE NEWSWIRE) -- [...]
IntelGenx Launches Preferred Share Regulation A Offering
20/02/2024
SAINT LAURENT, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced the launch of a Regulation A offering of up to 2,000,000 shares of Series A [...]
Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement
20/02/2024
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to [...]
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
20/02/2024
SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
20/02/2024
COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, [...]
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
20/02/2024
ORALTO Phase 3 trial focused on desired initial target indication of early oral step-down treatment of invasive aspergillosis infections in adults who have limited or no treatment options Non-inferiority trial will [...]
Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024
20/02/2024
TORONTO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that fourth quarter and fiscal year 2023 [...]
Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
20/02/2024
Publication pinpoints triggering of cGAS/STING pathway to activate immune defense mechanisms, as well as potentiation of anti-PD-L1 immune-mediated tumor cell killing, in triple-negative breast cancer xenograft model [...]
Theratechnologies annonce la publication d’un article dans Frontiers in Immunology qui approfondit la compréhension du mécanisme d’action moléculaire du sudocétaxel zendusortide (TH1902)
20/02/2024
MONTRÉAL, 20 févr. 2024 (GLOBE NEWSWIRE) -- L’article documente le déclenchement de la voie cGAS/STING, qui active des mécanismes de défense immunitaire et potentialise l’activité antitumorale de l’anti-PD-L1 dans un [...]
VitalHub UK Expands Healthtech Portfolio into Middle East through a Partnership with ADHDS
20/02/2024
TORONTO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX:VHI) (OTCQX:VHIBF) and its subsidiary, VitalHub UK (“VitalHub UK”) are pleased to announce the expansion of its digital [...]

Pages